Tumor Biology

, 32:1183 | Cite as

Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma

  • Xiao-Nan Sun
  • Wei-Guo Cao
  • Xin Wang
  • Qi Wang
  • Ben-Xing Gu
  • Qi-Chu Yang
  • Jian-Bin Hu
  • Hai Liu
  • Shu Zheng
Research Article


The purpose of this study was to evaluate the value of vascular endothelial growth factor-A (VEGF-A) expression and other confirmed prognostic factors in predicting clinical outcomes after the resection of gallbladder carcinoma (GBC). Between January 1999 and January 2006, a total of 84 consecutive and non-selected patients who underwent resection for GBC were retrospectively reviewed. Of the 84 patients studied, 45 cases (53.6%) exhibited high expression of VEGF-A and were placed into the high expression group. The 14 cases (16.7%) that showed no VEGF expression and the 25 cases (29.7%) that had lower VEGF-A levels were pooled into the low expression group (46.4%). There was a relationship between VEGF-A status and pM stage (P = 0.027) as well as histologic differentiation (P < 0.001). In univariate analysis by log-rank test, ECOG performance status, CA 19-9, pN stage, pM stage, histologic differentiation, and VEGF-A expression were significant prognostic factors (P = 0.015, 0.001, 0.020, <0.001, 0.040, and <0.001, respectively). Multivariate analysis revealed that pN status and VEGF-A expression maintained independent prognostic influence on overall survival (P < 0.001 and P = 0.013, respectively). VEGF-A expression has a positive correlation with pM stage and histologic differentiation. pN status and VEGF-A expression were independent prognostic factors of overall survival in patients with resected GBC.


Gallbladder carcinoma Vascular endothelial growth factor-A Prognosis 


Conflicts of interest



  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  2. 2.
    Furuse J. Postoperative adjuvant treatments for biliary tract cancer. J Hepatobiliary Pancreat Surg. 2008;15:463–7.PubMedCrossRefGoogle Scholar
  3. 3.
    de Aretxabala X, Roa I, Berrios M, Hepp J, Gallardo J, Cordova A, et al. Chemoradiotherapy in gallbladder cancer. J Surg Oncol. 2006;93:699–704.PubMedCrossRefGoogle Scholar
  4. 4.
    Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008;98:485–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Ito H, Matros E, Brooks DC, Osteen RT, Zinner MJ, Swanson RS, et al. Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. J Gastrointest Surg. 2004;8:183–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, et al. Adjuvant therapy for gallbladder carcinoma: the Mayo clinic experience. Int J Radiat Oncol Biol Phys. 2009;75:150–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Cho SY, Kim SH, Park SJ, Han SS, Kim YK, Lee KW, et al. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol. 2010;102:87–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Murakami Y, Uemura K, Hayasidani Y, Sudo T, Hashimoto Y, Ohge H, et al. Indication for postoperative adjuvant therapy in biliary carcinoma based on analysis of recurrence and survival after surgical resection. Dig Dis Sci. 2009;54:1360–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala Nirag C, Callens T, Messiaen L, et al. Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2010;1:76–89.Google Scholar
  10. 10.
    Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg. 2001;193:380–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A, Sivridis E. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol. 2003;29:879–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, et al. Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol. 2006;94:242–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76.PubMedCrossRefGoogle Scholar
  14. 14.
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27.PubMedCrossRefGoogle Scholar
  15. 15.
    Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–39.PubMedGoogle Scholar
  16. 16.
    Okita S, Kondoh S, Shiraishi K, Kaino S, Hatano S, Okita K. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol. 1998;12:1013–8.PubMedGoogle Scholar
  17. 17.
    Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds) (2002). American Joint Committee on Cancer Staging Manual. 6th ed. Springer, New York 139–144Google Scholar
  18. 18.
    Kokudo N, Makuuchi M, Natori T, Sakamoto Y, Yamamoto J, Seki M, et al. Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg. 2003;138:741–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Tsukada K, Kurosaki I, Uchida K, Shirai Y, Oohashi Y, Yokoyama N, et al. Lymph node spread from carcinoma of the gallbladder. Cancer. 1997;80:661–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res. 1999;19:2257–60.PubMedGoogle Scholar
  21. 21.
    Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol. 1995;177:275–83.PubMedCrossRefGoogle Scholar
  22. 22.
    Volm M, Koomägi R, Mattern J. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res. 1996;16:213–7.PubMedGoogle Scholar
  23. 23.
    Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O’Byrne K, Scott PA, et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 1998;4:3017–24.PubMedGoogle Scholar
  24. 24.
    Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000;60:3088–95.PubMedGoogle Scholar
  25. 25.
    Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, Horiuchi T, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet -derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. 1997;119:227–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Maeda K, Kang SM, Ogawa M, Onoda N, Sawada T, Nakata B, et al. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer. 1997;74:545–50.PubMedCrossRefGoogle Scholar
  27. 27.
    Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M, et al. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res. 1998;4:429–34.PubMedGoogle Scholar
  28. 28.
    Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999;79:1553–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Seki S, Fujiwara M, Matsuura M, Fujita S, Ikeda H, Asahina I, et al. Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors. Oral Oncol. 2011;47:588–93.PubMedCrossRefGoogle Scholar
  30. 30.
    Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg. 1996;224:639–46.PubMedCrossRefGoogle Scholar
  31. 31.
    Yamaguchi K, Nagino M, Oda K, Kamiya K, Uesaka K, Nimura Y. Perineural invasion has a negative impact on survival of patients with gallbladder cancer. Br J Surg. 2002;89:1130–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Fong Y, Jamagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg. 2000;232:557–69.PubMedCrossRefGoogle Scholar
  33. 33.
    Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4:695–706.PubMedCrossRefGoogle Scholar
  34. 34.
    Kayahara M, Nagakawa T, Nakagawara H, Kitagawa H, Ohta T. Prognostic factors for gallbladder cancer in Japan. Ann Surg. 2008;248:807–14.PubMedCrossRefGoogle Scholar
  35. 35.
    Lowenfels AB. Gallstones and glaciers: the stone that came in from the cold. Lancet. 1988;18:1385–6.CrossRefGoogle Scholar
  36. 36.
    Lowenfels AB, Maisonneuve P, Boyle P, Zatonski WA. Epidemiology of gallbladder cancer. Hepatogastroenterology. 1999;46:1529–32.PubMedGoogle Scholar
  37. 37.
    Liu Y, Qiu Y, Zhang X, Tian Y, Huang D, Zhou X, et al. The expression and correlation of HMGB1 and VEGF protein in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011;25:265–9.PubMedGoogle Scholar
  38. 38.
    Czito BG, Hurwitz HI, Clough RW, Tyler DS, Morse MA, Clary BM, et al. Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys. 2005;62:1030–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:167–75.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2011

Authors and Affiliations

  • Xiao-Nan Sun
    • 1
  • Wei-Guo Cao
    • 2
  • Xin Wang
    • 3
  • Qi Wang
    • 1
  • Ben-Xing Gu
    • 1
  • Qi-Chu Yang
    • 1
  • Jian-Bin Hu
    • 1
  • Hai Liu
    • 4
    • 5
  • Shu Zheng
    • 4
    • 5
  1. 1.Department of Radiation Oncology of Sir Run Run Shaw Hospital, Sir Run Run Shaw Institute of Clinical Medicine of Zhejiang UniversityZhejiang University School of MedicineHangzhouChina
  2. 2.Department of Oncology, Shanghai Ruijin HospitalMedical School of Shanghai Jiaotong UniversityShanghaiChina
  3. 3.Department of Medical Oncology, Zhongshan HospitalXiamen UniversityXiamenChina
  4. 4.Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical SciencesCancer InstituteHangzhouChina
  5. 5.The Second Affiliated HospitalZhejiang University School of MedicineHangzhouChina

Personalised recommendations